Co-administration of the adjuvanted recombinant zoster vaccine with other adult vaccines: An overview.

Publication date: Feb 28, 2024

The adjuvanted recombinant zoster vaccine (RZV; Shingrix(R), GSK) is a subunit vaccine that has been approved for the prevention of herpes zoster in adults. Co-administration of two vaccines in a single visit is a strategy to improve overall vaccine coverage. This review aims to consolidate available clinical data on RZV co-administration, providing an overview of safety, reactogenicity and immunogenicity. RZV co-administration data were obtained from five randomised, open-label, phase III clinical trials with similar study designs. The co-administered vaccines included: quadrivalent seasonal inactivated influenza vaccine (IIV4; NCT01954251), 23-valent pneumococcal polysaccharide vaccine (PPSV23; NCT02045836), reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine (Tdap; NCT02052596), 13-valent pneumococcal conjugate vaccine (PCV13; NCT03439657) and COVID-19 mRNA-1273 booster (NCT05047770). Eligible participants were healthy adults aged ≥50 years. A total of 3,974 participants were vaccinated (co-administration: 1,973; sequential: 2,001) across the five trials. Vaccine response rates to RZV were similar for co-administration (range: 95. 8-99. 1 %) and sequential groups (range: 95. 1-99. 1 %). Immune responses to RZV and the other vaccines (with the exception of pertactin) were non-inferior when the vaccines were co-administered compared with sequentially administered. Overall incidences of solicited local and general adverse events (AEs), unsolicited AEs, serious AEs or potential immune-mediated diseases were similar after co-administration or sequential administration. Myalgia was the most common solicited systemic AE (co-administration: 38-64 %; sequential: 30-59 %). Shivering and fever were more common after co-administration (16 % and 21 %, respectively) than after sequential administration (both 7 %) of RZV and PPSV23. Co-administration of RZV with routine vaccines does not significantly alter the reactogenicity, immunogenicity or safety of RZV or the co-administered vaccine. Healthcare practitioners should consider routine co-administration of RZV with other adult vaccines to improve vaccination coverage.

Open Access PDF

Concepts Keywords
Nct05047770 Adjuvanted
Pcv13 Administered
Recombinant Administration
Unsolicited Adults
Vaccine Co


Type Source Name
disease MESH zoster
disease VO vaccine
disease VO Shingrix
disease VO subunit vaccine
disease VO Optaflu
disease VO inactivated influenza vaccine
disease MESH diphtheria
disease MESH tetanus
disease VO Acellular Pertussis Vaccine
disease VO TDAP
disease VO conjugate vaccine
disease MESH COVID-19
disease VO vaccinated
drug DRUGBANK Bordetella pertussis pertactin antigen
disease MESH Shivering
disease VO vaccination coverage

Original Article

(Visited 1 times, 1 visits today)